Cutaneous sarcoidosis developing after treatment with pegylated interferon and ribavirin: a new case and review of the literature
Cutaneous sarcoidosis developing after treatment with pegylated interferon and ribavirin: a new case and review of the literature
复制标题
DOI：
10.1111/j.1365-4632.2010.04728.x
复制
发表时间：
2011-03-01
影响因子：
3.6
通讯作者：
Jorda, Esperanza
中科院分区：
文献类型：
--
作者：
Lopez, Veronica;Molina, Inmaculada;Jorda, Esperanza
结节病是一种多系统肉芽肿性疾病，影响20至50岁的成年人的多个器官。干扰素α (ifn - α)是一种免疫调节剂，已广泛用于多种疾病，包括丙型肝炎病毒感染、多发性硬化症和其他类型的肿瘤，包括白血病、淋巴瘤、卡波西氏肉瘤和黑色素瘤。标准的ifn - α诱导的结节病已经有报道，但很少有报道使用聚乙二醇化ifn - α治疗皮肤结节病。我们提出了一个新的皮肤结节病病例后，与聚乙二醇化IFN治疗，并回顾了文献。
Sarcoidosis is a multisystem granulomatous disease that affects multiple organs in adults between 20 and 50 years old. Interferon alpha (IFN-alpha) is an immunomodulator that has been used in a wide range of diseases, including hepatitis C virus infection, multiple sclerosis, and other types of neoplasias, including leukemia, lymphoma, Kaposi's sarcoma, and melanoma. Standard IFN-alpha-induced sarcoidosis has been reported, but there are few reports of cutaneous sarcoidosis with pegylated IFN-alpha therapy. We present a new case of cutaneous sarcoidosis after treatment with pegylated IFN, and a review of the literature.